Investigating the functionality of an OCT4-short response element in human induced pluripotent stem cells. by Vega-Crespo, Agustin et al.
UCLA
UCLA Previously Published Works
Title
Investigating the functionality of an OCT4-short response element in human induced 
pluripotent stem cells.
Permalink
https://escholarship.org/uc/item/5gk789kv
Authors
Vega-Crespo, Agustin
Truong, Brian
Hermann, Kip J
et al.
Publication Date
2016
DOI
10.1038/mtm.2016.50
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Citation: Molecular Therapy — Methods & Clinical Development (2016) 3, 16050; doi:10.1038/mtm.2016.50 
Official journal of the American Society of Gene & Cell Therapy 
www.nature.com/mtm
INTRODUCTION
Octamer-binding transcription factor 4 (OCT4) is a nuclear tran-
scription factor of the POU-homeodomain family. The role of OCT4 
in mammalian cells is critical in several aspects of embryonic stem 
cell maintenance including self-renewal and sustainment of toti-
potency or pluripotency, and for regulation of gene expression 
networks.1–4 Changes in its expression are involved in multiple 
developmental programs such as lineage commitment to primitive 
endoderm and mesoderm by its transient increase, and to troph-
ectoderm differentiation with its repression.5–8 The OCT4 promoter 
consists of both a (i) distal promoter, which mediates the molecular 
response for transcription via a putative OCT4-SOX2 binding site, 
and (ii) a proximal promoter, containing a retinoic acid, NANOG, 
estrogen and steroid-thyroid response element located within a 
region 3.1 kb upstream of the OCT4 gene. These are present as four 
conserved regions which can be methylated during embryogenesis 
and cell fate specialization9–12 (Figure 1a).
The mechanism of reprograming adult dermal fibroblasts 
modifies the epigenetic landscape by transient addition or 
genomic incorporation of four essential reprogramming factors 
(OCT4, SOX2, KLF4, and MYC13). As one of the OSKM factors, OCT4 
initiates chromatin rearrangement, gene transactivation, and 
pluripotency development.14–16 Additionally, OCT4 is used in part 
to maintain the pluripotent phenotype and for self-renewal.17 As 
mammalian cells undergo differentiation into somatic tissues, 
there is a loss in OCT4 expression.18,19 This regulation of OCT4 
is essential in tissue development and is orchestrated by feed- 
forward transcription, autoregulatory-promoting mechanisms, 
and by methylation-susceptible sequences20 that determine the 
timing of differentiation.21
Human induced pluripotent stem cells (hiPSCs) are a promising 
source of cells for autologous tissue engineering and therapeutic 
application; however, potential compromise of genomic integrity 
by genomic remodeling during cellular reprogramming and tumor-
igenic potential attributed to avid OCT4 activity represent safety 
concerns for their eventual clinical application.22–24 Specifically, 
OCT4 may act to promote malignancy,3 as its ectopic expression in 
somatic cells can cause epithelial dysplasia.25 Additionally, as OCT4 
protein expression gradually increases in different types of malig-
nant cells, it can promote tumorigenesis and inhibit cancer cell 
apoptosis26,27 and has been detected in both germ cell28–30 and vari-
ous human somatic tumors, including hepatocellular carcinoma,31 
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Function of OCT4SRE in pluripotent stem cells
Pluripotent stem cells offer great therapeutic promise for personalized treatment platforms for numerous injuries, disorders, and 
diseases. Octamer-binding transcription factor 4 (OCT4) is a key regulatory gene maintaining pluripotency and self-renewal of 
mammalian cells. With site-specific integration for gene correction in cellular therapeutics, use of the OCT4 promoter may have 
advantages when expressing a suicide gene if pluripotency remains. However, the human OCT4 promoter region is 4 kb in size, lim-
iting the capacity of therapeutic genes and other regulatory components for viral vectors, and decreasing the efficiency of homolo-
gous recombination. The purpose of this investigation was to characterize the functionality of a novel 967bp OCT4-short response 
element during pluripotency and to examine the OCT4 titer-dependent response during differentiation to human derivatives not 
expressing OCT4. Our findings demonstrate that the OCT4-short response element is active in pluripotency and this activity is in 
high correlation with transgene expression in vitro, and the OCT4-short response element is inactivated when pluripotent cells 
differentiate. These studies demonstrate that this shortened OCT4 regulatory element is functional and may be useful as part of an 
optimized safety component in a site-specific gene transferring system that could be used as an efficient and clinically applicable 
safety platform for gene transfer in cellular therapeutics. 
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breast cancer,32,33 and bladder cancer,34,35 suggesting that OCT4 has 
a role in both the embryo and in adult malignancies.
The purpose of this study was to characterize the functionality of 
a 967 bp OCT4-short response element (OCT4SRE) (Figure 1b) during 
pluripotency and differentiation; a shortened promoter would be 
useful in genomic modification vectors, providing additional space 
for therapeutic or other regulatory components. In addition, both 
viral vector titer and homologous recombination can be improved 
by smaller constructs and utilizing a shortened but functional pro-
moter will reduce the overall size. Finally, if pluripotency remains in 
a delivered therapeutic cell product, utilizing the OCT4SRE to drive a 
suicide gene as part of a therapeutic construct would allow for the 
removal of these cells and decrease the potential risk of unintended 
implantation of cells with pluripotency.
ReSUlTS
Construct delivery, OCT4 activation, and positive selection
AD2 fibroblasts were transduced with the OCT4SRE vector at 10 multi-
plicity of infection (MOI) and the High10% eGFP-expressing cells (mean 
fluorescence intensity ≥ 1 × 104) were collected by fluorescence-
activated cell sorting (FACS) purification. The purified fraction was 
expanded for 1 week and FACS-purified for eGFP, for a second time. 
The eGFP-expressing cells with a mean fluorescence intensity of 
~1 × 105 (>98%) were allowed to recover for 48 hours before begin-
ning lentivirus-based reprogramming to hiPSC (Figure 2a). These 
genetically modified cells, that constitutively expressed eGFP, were 
transduced for reprogramming at 10 MOI with stem cell cassette 
(STEMCCA). The cells were then seeded over a mouse embryonic 
fibroblast layer at day 7 and were inspected regularly prior to harvest-
ing the Stb-expressing putative hiPSC candidate clones at 21 days.
At day 10–14 after initiation of reprogramming, the Stb expression 
peaked, allowing visualization of the Stb-positive cell aggregates by 
fluorescence microscopy at low exposure time (<300 ms, second 
row) (Figure 2b). However, Stb fluorescence intensity decreased 
for the remaining days of the culture until reaching a consistent 
basal level at approximately day 21 (800–1,200 ms) (Figure 2b, third 
row). This decline of Stb fluorescence intensity is consistent with 
previous observations of OCT4 expression fluctuation during cel-
lular reprogramming where OCT4 expression peaks to commence 
Figure 1  Schematic of OCTS4SRE and vector constructs. (a) OCT4 expression is regulated by an upstream proximal enhancer (PE) and distal enhancer 
(DE). Comparison of human, bovine, and murine OCT4 5′ upstream sequences revealed four conserved regions (CR1–CR4) and these were combined 
with linkers to create the OCT4SRE. (b) Sequence of OCT4SRE with conserved regions are highlighted in green with CR4 → CR1 from top to bottom. 
Linkers between regions are unhighlighted. (c) Constructs were developed to test the OCT4-short response element (OCT4SRE) expressing strawberry 
fluorescent protein (Stb) in the reverse orientation while the constitutive elongation factor 1α promoter (EF1α) directed eGFP expression. (d) A second 
construct was developed that also provided coexpression of puromycin resistance (PURr) to the OCT4SRE by a porcine teschovirus-1 (p2A) linker. OCT4, 
Octamer-binding transcription factor 4; eGFP, enhanced green fluorescent protein.
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pluripotency development then returns to a substantially lower 
basal level in hiPSCs to maintain pluripotency.19 The putative hiPSC 
clones (now referred as C1) were then selected by examining for 
pluripotent-like cell morphology and eGFP/Stb-double positive 
expression; they were then converted to clinical grade (by growing 
in clinical grade pluripotent media and conditions).
After establishing the clinical grade pluripotent cultures, FACS 
purification of Stb/eGFP-double positive cells was performed for 
C1 and the Stb/eGFP-expressing subset was collected (Figure 3a), 
followed by 1 week recovery and FACS purification for Stb/eGFP a 
second time. The High35% Stb/eGFP-expressing cells, with a MFI ≥ 
5 × 103 for both colors, were collected for further investigations. Stb 
expression in the pluripotent state was further confirmed by immu-
nocytochemistry (ICC) against RFP (Figure 3b).
Evaluation of pluripotency
The putative AD2 hiPSC Stb/eGFP-double positive C1, AD2 hiPSC WT, 
and the nonpluripotent counterparts (AD2 fibroblasts OCT4SRE and 
AD2 fibroblasts WT) were examined by ICC for markers of canonical 
stemness for pluripotency, expecting these to have been activated 
through STEMCCA-based reprogramming (Figure 4).36 Both of the 
putative hiPSCs tested positive for the pluripotent immunopheno-
type. Both of the hiPSCs were positive for Nanog37 and OCT4,17,37 
having distinct functionality in initiating and maintaining the plu-
ripotent state. In addition, the putative hiPSCs highly expressed 
alkaline phosphatase (alkaline phosphatase is markedly increased 
in undifferentiated PSCs).38 Although the surface glycosphingolip-
ids stage-specific embryonic antigen 3 (SSEA-3) and stage-specific 
embryonic antigen 4 (SSEA-4) may not play critical functional roles 
in maintaining pluripotency, they are highly expressed on PSCs, 
have discrete multipotent abilities, and may potentiate reprogram-
ing efficiency,37,39 and therefore, were also examined and found 
to be positive on the hiPSCs. Finally, the transmembrane proteins 
TRA-1–60 and TRA-1–81 are avidly expressed by undifferentiated 
human PSCs, and while these are without an attributed pluripotent 
function, their expression is lost during differentiation40; both were 
positive on AD2 hiPSC C1. The fibroblasts tested negative for all the 
Figure 2 FACS-based purification plots of fibroblasts and OCT4SRE activity with reprogramming. (a) FACSAria cell sorter was pre-adjusted and calibrated 
to very high purity for all purifications. eGFP-positive fraction post-2x FACS SORT was collected for OCT4 activation by reprogramming adult somatic 
cells to hiPSC. (b) Live imaging of AD2 cells with genetic modification where DsRed = Stb expression driven by OCT4SRE and eGFP = EF1α-eGFP. Orange 
arrow = AD2 fibroblasts (eGFP-positive fraction post-2x FACS SORT); blue arrow = day 10–14 high Stb-expressing reprogramming cell aggregates; 
and purple arrow = eGFP/Stb-double positive putative AD2 hiPSC on CGPM at day 21. (Bar = 200 μm). CGPM, clinical grade pluripotent media; eGFP, 
enhanced green fluorescent protein; EF1α, elongation factor 1α; FACS, fluorescence-activated cell sorting; hiPSC, human induced pluripotent stem cell; 
OCT4, octamer-binding transcription factor 4; OCT4SRE, OCT4-short response element.
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markers except SSEA-3 which was weakly positive; this has been 
previously reported elsewhere.39
We did detect a small number of fibroblasts as being RFP positive, 
suggesting that there was some off-target activity of the OCT4SRE 
(Figure 4). To further examine the sensitivity and off-target activity 
of the OCT4SRE in OCT4-negative cells, we performed flow cytom-
etry comparing the number of eGFP/Stb-double positive AD2 
fibroblasts with Stb driven by the OCT4SRE and the full-length OCT4 
 promoter. We found that off-target expression by the full-length 
OCT4 promoter and OCT4SRE occurred in approximately 0.4% and 
3.2% of cells, respectively (see Supplementary Figure S1).
The ability of these hiPSCs to differentiate into the three germ 
 layers was evaluated in vitro utilizing the d-Stem Tri-lineage differen-
tiation kit. The lineage-specific differentiation was assessed with vali-
dated antibodies (listed in Table 1) to: (i) Brachyury, a protein encoded 
by the T gene and initiates early cellular differentiation into meso-
derm and axis differentiation; (ii) SOX17, a transcriptional regulator 
promoting endoderm formation, allowing for cellular differentiation 
by indirectly antagonizing self-renewal; and (iii) SOX1 which regu-
lates neural plate delineation, ectoderm and neural determination41,42 
(see Supplementary Figure S2). The lines demonstrated their ability to 
differentiate into all three germ layers confirming pluripotency.
In vitro functional response and OCT4SRE inactivation
After 1 week of dermal culture media (DCM) conditioning, AD2 
hiPSC C1 demonstrated robust eGFP expression and a very low 
OCT4SRE-mediated Stb expression by ICC (see Supplementary 
Figure S3, RFP column for C1). The morphologic appearance of the 
pluripotent cells in the cultures drastically changed during the first 
48 hours in DCM, acquiring a flattened fibroblast-like appearance 
with a noticeable reduction in their self-renewability.
To investigate the in vitro functional response of the OCT4SRE, 
AD2 hiPSC WT were transduced with lenti-pRRL-sin-cPPT-rPAC-
rp2A-rStb-rOCT4SRE-EF1α-eGFP (now referred as C1P) and were 
Figure 3 FACS-based purification plots of human induced pluripotent stem cells (hiPSCs) and OCT4SRE activity. (a) The 
High35% Stb/eGFP-double 
positive fraction post-2x FACS SORT was collected. (b) Indirect OCT4SRE-mediated Stb expression assessment was performed after OCT4 activation by 
reprogramming to hiPSC by ICC staining for RFP where blue = DAPI, RFP = Stb expression driven by OCT4SRE, eGFP = EF1α-eGFP. (Bar = 200 μm). eGFP, 
enhanced green fluorescent protein; EF1α, elongation factor 1α; FACS, fluorescence-activated cell sorting; hiPSC, human induced pluripotent stem cell; 
OCT4, octamer-binding transcription factor 4; OCT4SRE, OCT4-short response element.
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puromycin-selected. AD2 hiPSC C1P were then FACS-purified for 
Stb/eGFP-double positive cells, puromycin-selected, and FACS-
purified a second time to collect the High35%-Stb/eGFP-double 
positive cells before DCM conditioning. Puromycin (1 μg/ml) was 
then added to the AD2 hiPSC C1P-derived DCM-treated cultures 
for 96 hours. Puromycin selection permits the pluripotent cells 
(that is, those cells expressing OCT4 to drive OCT4SRE-mediated 
puromycin resistance (see Figure 1c)) to proliferate under puro-
mycin treatment. Thus, high OCT4-expressing hiPSCs will have 
high OCT4SRE-mediated puromycin resistance, whereas the dif-
ferentiated derivatives will have low or no OCT4 expression and 
thus, no puromycin resistance resulting in negative selection 
(i.e.,  cell death). Addition of puromycin was toxic to the AD2 
hiPSC WT and C1P-derived DCM derivatives (DCM-d) causing 
complete cell death after 96 hours of exposure, demonstrating 
the efficacy of the serum-based treatment to promote spontane-
ous differentiation and, thus, OCT4SRE inactivation (with loss of 
puromycin resistance).
Figure 4 Immunophenotyping of hiPSCs confirms pluripotency as cells can be differentiated into the three germ layers. AD2 hiPSC where alkaline 
phosphatase (AP), stage-specific embryonic antigens 3 (SSEA-3) and 4 (SSEA-4), tumor-related antigen 1–60 (TRA 1–60) and 1–81 (TRA 1–81) octamer-
binding transcription factor 4 (OCT4), and transcription of homeobox protein Nanog were tested. Stb (RFP), eGFP and phase images were collected 
for each cell type to demonstrate construct expression. Cell types of images from top to bottom are: AD2 fibroblasts wild type (WT), AD2 fibroblasts 
post-2x FACS-purified for eGFP (OCT4SRE), AD2 hiPSC wild type (WT), AD2 hiPSC Clone 1 expressing Stb/eGFP (C1). FACS, fluorescence-activated cell 
sorting; hiPSC, human induced pluripotent stem cell; eGFP, enhanced green fluorescent protein; OCT4SRE, OCT4-short response element.
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Table 1 Primary and secondary antibodies
  
Primary antibody Secondary antibody
Reference DilutionReference Dilution Isotype
Nanog Abcam, ab21603 1:100 Goat anti-Rabbit IgG 
(H+L) Alexa Fluor 647
Life Technologies, A-21244 1:200
OCT4 SCBT, SC-5279 1:200 Goat anti-Mouse 
IgG2b Alexa Fluor 647
Life Technologies, A-21242 1:200
RFP Rockland, 600-401-379 1:250 Goat anti-Rabbit IgG 
(H+L)Alexa Fluor 555
Life Technologies, A-21428 1:200
SSEA-3 Millipore, mab4303 1:200 Goat anti-Rat IgM, µ 
Chain DyLight 649
Jackson Laboratories, 112-
496-075
1:200
SSEA-4 Millipore, mab4304 1:200 Goat anti-Mouse 
IgG2b Alexa Fluor 647
Life Technologies, A-21242 1:200
TRA 1–60 Millipore, mab4360 1:200 Goat anti-Mouse IgM 
(H+L) Alexa Fluor 647
Life Technologies, A-21238 1:200
TRA 1–81 Millipore, mab4381 1:200 Goat anti-Mouse IgM 
(H+L) Alexa Fluor 647
Life Technologies, A-21238 1:200
Brachury MicroStem, MS052013 1:10 Goat anti-Rabbit IgG 
(H+L) Alexa Fluor 647
Life Technologies, A-21244 1:200
Sox17 MicroStem, MS052013 1:10 Goat anti-Mouse IgM 
(H+L) Alexa Fluor 647
Life Technologies, A-21238 1:200
Sox1 MicroStem, MS052013 1:10 Donkey anti-Goat IgG 
(H+L) DyLight594
Abcam, ab96937 1:200
OCT4, octamer-binding transcription factor 4; OCT4SRE, OCT4-short response element; SSEA-3, stage-specific embryonic antigen 3; SSEA-4, stage-specific 
embryonic antigen.4; TRA (1–60), tumor-related antigen 1–60; TRA (1–81), tumor-related antigen (1–81).
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To further confirm this result, replicate cultures of (i) fibroblasts, 
(ii) High35% Stb/eGFP-expressing hiPSCs, and (iii) DCM-d (i.e., spon-
taneously differentiated cells) were analyzed by flow cytometry for 
quantitative protein detection (Figure 5) and by quantitative poly-
merase chain reaction (qPCR) to assess the transcript level (Figure 6). 
AD2 fibroblasts post-2x FACS purification expressed eGFP in 96% of 
cells; <3% were Stb/eGFP-double positive. With STEMCAA repro-
gramming to pluripotency, the post-2x FACS purification for Stb 
demonstrated AD2 hiPSCs with Stb/eGFP-double positive expres-
sion in ≥ 90% of cells. Thus, the hiPSCs developed OCT4SRE activity 
during pluripotency as detected by the substantial increase in Stb/
eGFP-double positive cells. After 1 week the media was changed to 
DCM with fetal bovine serum (FBS) (i.e., inducing cellular differentia-
tion), the AD2 DCM-derivatives (DCM-d) revealed a statistically sig-
nificant (P = 0.0001) decrease of the Stb/eGFP-double positive cells 
from the pluripotent state; this decrease was from ≥ 90% in hiPSCs 
to < 1% in the differentiated DCM-d.
We measured the target transcript levels of OCT4SRE-mediated Stb 
expression. This demonstrated significantly higher Stb (P = 0.008) 
and OCT4 (P = 0.006) RNA expression during pluripotency (hiPSC) 
(Figure 6, panel 1, center bars) versus the parental genetically modi-
fied fibroblasts and the differentiated DCM-d (Figure 6, panel 1, outer 
bars); OCT4 and Stb transcript RNA expression was 2–3 logs higher 
than fibroblasts and DCM-d while maintained with pluripotency. 
Transcript levels of OCT4SRE and Stb fluctuate in equal degree during 
reprogramming and differentiation, indicating a direct correlation 
between OCT4 and Stb mRNA levels. We would expect OCT4 not to 
be active in these latter two conditions, and there were no statisti-
cal difference for the expression of these genes in these cell states 
(P = 0.235). The OCT4SRE-Stb transcript content of the parental hiP-
SCs and the hiPSC-derived mesoderm-, endoderm-, and ectoderm-
like cells displayed RNA transcript levels for both OCT4 and Stb in 
ectoderm and endoderm, while mesoderm showed the lowest RNA 
expression among the derivatives (Figure 6, panel 2). The Pearson 
Figure 5 OCT4SRE shows an off-on-off pattern with fibroblast reprogramming to hiPSC to differentiation to dermal derivatives. FACS analysis plots of AD2 
cells with genomic modification: Orange arrow = AD2 fibroblasts eGFP-positive fraction post-2x FACS SORT demonstrating that OCT4SRE-transcriptional 
regulatory activity is off. Blue arrow = High35% Stb/eGFP-expressing AD2 hiPSC clone C1 OCT4SRE activity on. Purple arrow = DCM (differentiated) 
derivatives clones C1 with OCT4SRE activity off. WT = Wild Type. OCT4SRE = OCT4-short response element. eGFP = enhanced green fluorescent protein. 
PE:TexasRed = Stb. Percentages on the quadrant-corners of the FACS plots represent the average of triplicate measurements where green = eGFP only, 
blue = Stb/eGFP-double negative, red = Stb/eGFP-double positive, black = Stb only. FACS, fluorescence-activated cell sorting; hiPSC, human induced 
pluripotent stem cell; OCT4, octamer-binding transcription factor 4; DCM, dermal culture media.
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correlation analysis with a coefficient r2 = 0.965 (n = 15) confirms a 
direct statistically significant correlation of OCT4/Stb mRNA across 
the clones and culture conditions.
OCT4SRE-mediated cellular toxicity with thymidine kinase and 
ganciclovir
As previously described, high OCT4 expression during pluripo-
tency promotes OCT4SRE-mediated transgene expression. While the 
OCT4SRE-driven RFP expression as measured by fluorescence micros-
copy was relatively low in AD2 hiPSC C1P, OCT4SRE demonstrated func-
tional and specific OCT4SRE-driven antibiotic resistance (puromycin). 
In order to eventually apply such technology for treatment of urea 
cycle disorder (arginase deficiency), we developed a preclinical bidi-
rectional third generation lentivirus. This vector is pRRL-sin-cPPT-
rArgO-rEF1α-OCT4SRE-eGFP-F2A-PAC-P2A-TKO (ArgO, arginase 1 
codon optimized) for single-vector gene transfer of OCT4SRE-driven 
expression of a relevant suicide gene (human codon optimized 
Herpes simplex virus 1 SR39 thymidine kinase (TKO)) and a urea 
cycle enzyme needed for metabolism of nitrogen. (Functional 
recovery of arginase in arginase-deficient hiPSCs is not further 
examined as part of the scope of this manuscript.) Here, we demon-
strate that transduction of AD2 hiPSC WT cells with this preclinical 
vector conferred OCT4SRE-driven expression of eGFP and puromy-
cin resistance as well as TKO-mediated cell death) (Figure 7). Under 
live fluorescence microscopy, OCT4SRE-expressing AD2 hiPSC-TKO 
drove eGFP expression, but eGFP was not visible after conversion 
to DCM-d (AD2 DCM-d-TKO) (Figure 7a). OCT4SRE-expressing AD2 
hiPSC-TKO promoted expression of TKO and eGFP (and conferred 
puromycin resistance) while conversion to DCM-d resulted in sig-
nificant decline of OCT4 expression level (P < 0.0001) (n = 3) and 
significant loss of TKO (P < 0.0001) (n = 3) and eGFP (P < 0.0013) (n = 
3) RNA expression measured via quantitative reverse-transcriptase 
PCR (Figure 7b). Pearson correlation analysis between OCT4SRE-TKO 
(n = 3) and OCT4SRE-eGFP (n = 3) showed coefficients of r
2 = 0.998 
and r2 = 0.971, respectively, confirming direct statistically significant 
correlation between OCT4 expression levels and the transgenes 
regulated by OCT4SRE.
We then performed an in vitro TKO functional assay to determine 
the applicability and relevance of TKO as a suicide gene transfer 
modulator for induced cell death under the control of OCT4SRE. 
OCT4SRE-expressing AD2 hiPSC-TKO and DCM-d-TKO and their WT 
counterparts were evaluated for their OCT4SRE-mediated TKO func-
tional response to ganciclovir (GCV) administration. After 72hours 
of 2 μmol/l GCV supplementation, we attained 100% GCV-mediated 
cell death in only OCT4SRE-expressing AD2 hiPSC-TKO cells and no 
visible cell death in AD2 DCM-d-TKO, WT counterparts, and vehicle 
control cells (Figure 7c). These results demonstrate OCT4SRE-driven 
TKO expression conferring induced cell death after GCV treatment 
only during an OCT4-expressing cell state.
DISCUSSION
During embryonic development, OCT4 is expressed in the early 
zygote and morula and initially in all blastomeres, with subsequent 
restricted expression to the inner cell mass. OCT4 expression is then 
downregulated in the trophectoderm and the primitive endoderm 
and, at maturity, expression becomes confined exclusively to the 
developing germ cells, being negative in differentiated lineages.43,44 
Targeted disruption of OCT4 in mice has produced embryos devoid 
of a pluripotent inner cell mass,7 suggesting that OCT is essential for 
maintaining pluripotency and is a key regulator of stem cell differ-
entiation; its activity must be tightly regulated to ensure the proper 
differentiation of various tissues and organs.1
In this investigation, we have demonstrated the functional 
in vitro competence of a 967 bp reduced OCT4 promoter as a func-
tional dynamic response element during pluripotency. As OCT4 
levels are reduced with cellular differentiation, OCT4SRE inactivation 
occurs. These findings show that in this culture system and with the 
given experimental parameters, OCT4SRE promotes transcription 
directly modulated by OCT4 expression switching on when pluri-
potency is initiated and off when cells differentiate. In these stud-
ies, OCT4SRE-Stb/EF1α-eGFP transduced fibroblasts demonstrated 
very low OCT4SRE activity as shown by Stb expression in only 3% 
of transduced fibroblasts, while at the same time the vast major-
ity of cells (96%) demonstrated GFP expression by the constitutive 
promoter. In contrast, OCT4 overexpression during early stages of 
reprogramming (day 10–14) was visually detected by a Stb expres-
sion peak and decline, which corresponds to OCT4 activity during 
reprogramming.45,46
 Moreover, when these cells completed reprogramming to plu-
ripotency, the vast majority (91%) demonstrate OCT4-mediated 
activity of the short response element. When these hiPSCs under-
went differentiation through the conversion from clinical grade 
pluripotent media (CGPM) to FBS-containing DCM, activity of the 
OCT4SRE turned off as <1% of cells showed Stb expression; this 
demonstrated a quantifiable reduction of Stb expression from 91% 
at OCT4-high titers during pluripotency while the majority of the 
remaining population continued to express GFP (85%). In addition, 
further OCT4SRE inactivation in DCM conditions was illustrated by 
loss of puromycin resistance and complete cell death after 96 hours 
of puromycin treatment. Furthermore, we were able to demonstrate 
that this reduced size promoter was sufficiently effective in driving 
Figure 6 Quantitative real time PCR data analysis of OCT4SRE activity. 
Quantitative PCR for blue = OCT4 and red = Stb of AD2 fibroblasts, 
hiPSC and DCM-derivatives (DCM-d) where meso = mesoderm, endo 
= endoderm, ecto = ectoderm. Log Relative Gene Expression (RGE) is 
on the y-axis. Error bars represent mean ± SD (n = 9). Black * indicates 
significance P < 0.05 between experimental groups. hiPSC, human 
induced pluripotent stem cell; OCT4, octamer-binding transcription 
factor 4; DCM, dermal culture media; OCT4SRE, OCT4-short response 
element; PCR, polymerase chain reaction.
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thymidine kinase activity such that when supplemented with the 
prodrug GCV, death of only pluripotent cells occurs (while differen-
tiated DCM-d cells remain viable).
Overall, these findings in human cells demonstrate the regula-
tion of pluripotency by OCT4 expression described in vivo in mice, 
and at the same time show that a reduced OCT4 construct size of 
967 bp (from 4 kb) remains functional during pluripotency and 
remains regulatable with differentiation (whether as dermal fibro-
blasts or as FBS-mediated differentiated derivatives). To our knowl-
edge this functional OCT4 activity has only previously been shown 
with murine cells and is the first functional description of this phe-
nomenon in a human in vitro model and with a shortened response 
element.
The ability to condense the OCT4 responsive elements poten-
tially allows greater use of the limited genome size in vector devel-
opment. This would not only allow the use of therapeutic genes but 
also safety elements in a vector construct. It is generally accepted 
that retroviral and adeno-associated viral particles are capable 
of packaging vector genomes that are shorter or approximately 
the same length and, in some cases, slightly above the wild-type 
proviral genome (9.7 kb in the case of lentivirus and 4.7 kb in the 
case of adeno-associated viral), and that there is a sharply demar-
cated upper limit on the length of genomic material capable of 
being encapsidated.47 This packaging limit partially determines 
the utility of the vector for gene delivery purposes48 as generally 
titer decreases as insert size and proviral genome length increase. 
Multigenic and regulatable vectors and vectors with extensive pro-
moter, enhancer, or other noncoding sequences (such as homolo-
gous arms) will likely be useful in a variety of experimental and 
therapeutic settings48; these may be of greater length than standard 
vector constructs and thus, finding areas where elements may be 
decreased in size are important in vector development.
hiPSCs hold immense potential for the future of personalized 
cellular therapeutics in the treatment of a wide range of human 
conditions. However, to achieve their full therapeutic capabilities, 
transgenic safety elements should be considered and efficient and 
broadly applicable approaches will assist in their future adoption. 
We have demonstrated that the OCT4SRE, a 967 bp short response 
element, could potentially serve a functional role to remove 
unwanted pluripotent stem cell derivatives in vitro and after in vivo 
post-transplantation in site-specific targeting delivery in genomic 
modification for single gene disorders. In these in vitro studies, we 
have shown the OCT4SRE as a promising modulator of puromycin-
induced cell death for in vitro hiPSC purification and as a driver for 
GCV-mediated cell death promoting the expression a codon opti-
mized HSV1-SR39 TKO sequence for suicide gene transfer-induced 
cell death.
Advances in site-specific gene transferring have been achieved by 
CRISPR/Cas9-based genomic editing and is being applied to PSCs. We 
believe that a construct that incorporates the OCT4SRE and a suicide 
Figure 7 Examining the functionality of the OCT4SRE promoter in ganciclovir-mediated cell killing. (a) AD2 hiPSCs transduced with vector encoding 
OCT4SRE-eGFP-PURr-TKO (AD2 hiPSC-TKO) and AD2 hiPSC-TKO-derived nonpluripotent DCM-d (DCM-d-TKO). OCT4SRE-driven eGFP and puromycin 
resistance (PURr) were only expressed in OCT4-expressing hiPSC-TKO. (TKO = Thymidine Kinase codon optimized. (Bar = 200 µm). (b) Quantitative real 
time PCR data analysis of OCT4SRE activity. Quantitative PCR for red = AD2 hiPSC and blue = AD2 DCM-d for wild type (WT) and OCT4SRE-TKO-eGFP-
expressing cells. Log Relative Gene Expression (RGE) is on the y- axis. Error bars represent mean ± SD (n = 3). * indicates significance P < 0.05 between 
experimental groups. (c) Live microscopy demonstrated complete OCT4SRE-driven TKO-mediated cell death after 72-hours of 2 µm ganciclovir (GCV) 
administration to hiPSC-TKO, but not DCM-d-TKO determined via visual assessment. After OCT4SRE inactivation, DCM-d-TKO was viable and replicative 
during GCV treatment. (Bar = 200 µm). eGFP, enhanced green fluorescent protein; hiPSC, human induced pluripotent stem cell; OCT4, octamer-binding 
transcription factor 4; DCM, dermal culture media; OCT4SRE, OCT4-short response element; PCR, polymerase chain reaction.
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gene can provide both an efficient platform for single gene transfer 
into a genomic safe harbor while at the same time providing a suicide 
element in the case of remaining pluripotency. This reduced construct 
may provide a broadly applicable safety element for clinical application.
MATeRIAlS AND MeTHODS
OCT4SRE synthesis
The OCT4 gene minimal promoter element demonstrates functionality in 
murine cells by the regulatory action of distal and proximal enhancers upstream 
to a 380 bp minimal OCT4-promoter region (Figure 1a).11,12 The OCT4 (3.9 kb) 
promoter was obtained from Addgene (www.addgene.org, plasmid #38776) 
and was used to develop the full-length construct. The upstream elements, 
proximal enhancers and distal enhancers display four conserved regions 
of 563 bp (CR1-to-CR4) (Figure 1a) critical for regulation of OCT4 promoter 
with a sequence homology of 69–96% between murine, bovine, and human 
orthologs.9 However, the mapping of these four regions is not exact in their 
detail. Consequently, we decided to include additional sequences upstream or 
downstream of these four CRs to avoid omitting important  surrounding regu-
latory sequences and also to provide space to prevent functional interference 
between the regulatory domains. Thus, this OCT4 SRE  construct consists of 5' 
(CR4 = 648–779 plus 780–893), fused to (1227–1248 plus CR3 = 1249–1353 
plus 1354–1397) fused to (1620–1694 plus CR2 = 1695–1890 plus 1891–1957) 
fused to (2999–3074 plus CR1 3075–3204) as a 967 bp construct (Figure 1b) 
and was cloned into a standard pUC57 provided with HindIII and NcoI restric-
tion sites (Genewiz, South Plainfield, NJ). The OCT4 sequence number is based 
on the OCT4 sequence Genbank Ref AJ297527.1.
Vector design and construction
The pRRL-sin-cPPT-rStb-rOCT4SRE-EF1α-eGFP (Stb = strawberry fluorescent 
protein) lentiviral vector (Figure 1c) was constructed by PCR cloning of plas-
mid EF1α-eGFP (provided by UCLA Vector Core) with primers 5′-EF1α-ClaI 
(5′-CGT AAT CGA TCG TGA GGC TCC GGT GCC-3′) and 3′-GFP-SalI (5′-GCT AGT 
CGA CTT ACT TGT ACA GCT CGT CCA TG CC-3′), then digested and ligated 
into the plasmid pRRL-sin-cPPT-MCS (provided by UCLA Vector Core). The 
strawberry fluorescent protein (Stb) lacking a start codon was cloned into 
the 5′ end EF1α-eGFP in reverse orientation using primers 5′-rStb(-ATG)-
PmlI-EcoRI (5′-GCA TGA ATT CCA CGT GAG CAA GGG CGA GGA GAA TAA-3′) 
and 3′-rStb-XbaI (5′-GCA TTC TAG ATT ACT TGT ACA GCT CGT CCAT GCC-3′). 
The OCT4SRE promoter was subcloned by digesting phOCT4SRE plasmid-eGFP 
with HindIII and NcoI, blunting, and ligating into the previous construct 
digested with PmlI. The resulting plasmid provided a start codon to Stb 
driven by OCT4 and in an opposite orientation of the EF1α-eGFP. Similarly 
the full-length OCT4 promoter was removed from plasmid #38776 by restric-
tion enzyme digestion and subcloned into the construct.
The pRRL-rPAC-rp2A-rStb-rOCT4SRE-EF1α-eGFP (Figure 1d) was cloned 
by PCR of puromycin N-acetyl-transferase (PAC) with primers 5′-PAC-P 
(5′-ATG ACC GAG TAC AAG CCC ACG GTG CGC-3′) and 3′-PAC-SalI (5′-GCT 
AGT CGA CTC AGG CAC CGG GCT TG CG-3′) from a PAC-containing plas-
mid (provided by the UCLA Vector Core), then digested and ligated with 
pRRL-EF1α-Stb-p2A digested with SmaI and SalI. PCR was then performed 
on the resulting construct with primers 5′-mid-rStb-SbfI (5′-CTC CTC CCT 
GCA GGA CGG CGA GTT-3′) and 3′-PAC-XbaI (5′-GCA TTC TAG ATC AGG 
CAC CGG GCT TGC GG-3′), followed by digestion and ligation into vector 
pRRL-sin-cPPT-rStb-rOCT4SRE-EF1α-eGFP.
The pRRL-sin-cPPT-rArgO-rEF1α-OCT4SRE-eGFP-F2A-PAC-P2A-TKO was 
cloned by a two-step process of introducing the transgenes to a previ-
ously constructed plasmid, pRRL-sin-cPPT-MCS-rEF1α-OCT4SRE-MCS. The 
multiple cloning site (MCS) downstream of OCT4SRE was cut with PacI 5′ 
and SalI 3′. Transgene eGFP-F2A-PAC-P2A-TKO was isolated from plas-
mid pRRL-sin-cPPT-CMV-eGFP-F2A-PAC-P2A-TKO by PCR using primers 
5-GFP-PacI (GCTATTAATTAAACCATGGCCAGCAAGGGCG) and 3-TKO-SalI 
(GCATGTCGACTCAGTTGGCTTCGCCCATTTCC) to create 5′ PacI and 3′ SalI 
sequences flanking the transgene. PCR product was then digested with 
both restriction enzymes and ligated downstream of OCT4SRE. Construct 
pRRL-sin-cPPT-MCS-rEF1α-OCT4SRE-eGFP-F2A-PAC-P2A-TKO was then cut 
upstream of the reverse EF1α promoter using restriction enzymes SpeI 5′ and 
KpnI 3′. Transgene ArgO was produced from plasmid pRRL-sin-cPPT-HPRT-
Exon1-LHA-EF1α-ArgO-IRES-PAC-HPRT-Exon1-RHA by PCR with 5-ArgO-KpnI 
(GCTAGGTACCATGAGCGCAAAGTCACGCACCAT) and 3-ArgO-SpeI (GCATAC 
TAGTTTATTTAGGAGGGTTCAGGTAATCGATAGGC) and digested with the 
respective restriction enzymes. ArgO was then ligated into digested pRRL-sin-
cPPT-MCS-rEF1α-OCT4SRE-eGFP-F2A-PAC-P2A-TKO in reverse orientation to 
coincide with the EF1α promoter to produce the final vector product.
The lentiviral vectors (rStb-rOCT4SRE-EF1α-eGFP, rPAC-rp2A-rStb-rOCT4SRE-
EF1α-eGFP, rStb-rOCT4-EF1α-eGFP, and rArgO-rEF1α-OCT4SRE-eGFP-F2A-
PAC-P2A-TKO) were generated by transient transfection of 293T cells with a 
three packaging plasmid combination, as described previously,49 and with the 
specific pRRL plasmid for each lentiviral vector: pMD.G was used for the pro-
duction of the VSV-G viral envelope in combination with the packaging con-
structs pMDLg/pRRE and pRSV–REV. Briefly, 100 mm dishes of nonconfluent 
293T cells were transfected with 6.5 μg of pMDLg/pRRE, 3.5 μg of pMDG, 2.5 
μg of pRSV–REV (all three provided by Luigi Naldini, University of Torino, Italy) 
and 10 μg of pRRL-rStb-rOCT4SRE-EF1α-eGFP, pRRL-rPAC-rp2A-rStb-rOCT4SRE-
EF1α-eGFP, rStb-rOCT4-EF1α-eGFP, or rArgO-rEF1α-OCT4SRE-eGFP-F2A-PAC-
P2A-TKO by calcium phosphate precipitation.50,51 The next day, the cells were 
washed with phosphate-buffered saline (PBS) and were incubated with media 
containing 10 mmol/l sodium butyrate for 8 hours to obtain high-titer virus 
as previously described.52 After 8 hours, cells were washed with PBS and 
incubated in fresh media without sodium butyrate. Media was harvested 16 
hours later and passed through a 0.45 µm filter. Viral titer was determined by 
assessing viral p24 antigen concentration by enzyme-linked immunosorbent 
assay (Alliance HIV-I p24 ELISA Kit, Perkin Elmer, Waltham, MA) and hereafter 
expressed as μg of p24 equivalent units per ml.53
For transduction of 293T cells, cells were seeded at 2 × 105 cells per well 
and incubated at 37°C overnight in their regular media. Transductions were 
carried out in 1 ml of Dulbecco’s modified Eagle media, including serial dilu-
tions of lentiviral vector supernatant. The cells were then washed with PBS 
24 hours post-transduction and incubated in regular media for 48 hours.
Cellular reprogramming
The humanized single excisable lentiviral STEMCCA as lentiviral vectors were 
used to reprogram fibroblasts to pluripotency and were kindly provided by 
Dr Donald Kohn (UCLA) and produced as described elsewhere.54
In vitro culture of primary human skin cells
All procedures were approved by the Institutional Review Board (IRB#13-
001469-AM-00002) at the University of California, Los Angeles and informed 
consent was obtained from all individuals. The deidentified human fibro-
blast cell line AD2 utilized in this study was obtained from a 4 mm skin punch 
biopsy. Plastic-adherent cells proliferated in DCM consisting of Dulbecco’s 
modified Eagle media nutrient mixture (DMEM/F-12, Life Technologies, 
Carlsbad, CA catalog number 11320-082) supplemented with 10% FBS 
(Atlanta Biologicals, Flowery Branch, GA, catalog number S10650), 1% MEM 
nonessential amino acids (Life Technologies, catalog number 11140-076), 
2  mmol/l GlutaMAX (Life Technologies, catalog number 35050–061), and 
100 μg/ml Primocin (Invivogen, San Diego, CA; catalog number ant-pm-1). 
The culture media was changed every 2 days. The cells were allowed to 
expand to >90% confluency before passaging with 0.05% trypsin- ethylene 
diamine tetra acetate (Gemini Bio-Products, West Sacramento, CA, catalog 
number 400-150) and seeded at 4,400 cells/cm2.36,55
Genetic modification of adherent human dermal cells
1 × 105 AD2 fibroblasts were transduced with lenti-pRRL-sin-cPPT-rStb-
rOCT4SRE-EF1α-eGFP, a bidirectional third generation lentivirus encoding 
5′→3′ eGFP driven by human EF1α promoter and 3′→5′ Stb driven by the 
OCT4SRE. This was performed with 4 µg/ml polybrene (Millipore, Billerica, MA, 
catalog number TR-1003-G) at an MOI of 10.39,56 Cells were allowed to recover 
and then reseeded as described above. At 1 week post-lentiviral transduc-
tion, ~2.5 × 106 cells were trypsinized and washed twice with ice-cold PBS, 
passed through a 40 µm filter to remove clumps, and then resuspended in 
1 ml of ice-cold PBS and immediately analyzed and FACS-purified for eGFP 
on a FACSAria cell sorter (BD Biosciences, San Jose, CA). All FACS analyses 
were performed in triplicate. 4’,6-diamidino-2-phenylindole (DAPI)-stained 
(Life Technologies, D1306), dead-cell exclusion and doublet-exclusion gat-
ing was performed, and viable single-cell subpopulations were sorted using 
BD FACSDiva Software version 6.1.3 (BD Biosciences).39 eGFP-positive puri-
fied fractions were allowed to recover and then expanded for 1 week before 
a second round of FACS purification.
OCT4-mediated activation and positive selection
OCT4 activation of AD2 fibroblasts was achieved by hiPSC generation using 
STEMCCA.54 The reprogramming cultures were scrutinized weekly and candi-
date Stb-expressing hiPSC clones were selected 28 days post-STEMCCA trans-
duction and allowed to expand in CGPM consisting of a 50:50 blend of mTeSRII 
(StemCell Technologies, Vancouver, BC, catalog number 5860) and Nutristem 
(Stemgent, Cambridge, MA, catalog number 01-0005) with Primocin on 
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Vitronectin XF-(StemCell Technologies, catalog number 7180) coated 
plates following the manufacturer’s recommendations.56,57 Once each Stb-
expressing putative hiPSC clone reached >80% confluency with ~5 × 106 cells, 
the cells were incubated at 37°C with Y-27632 (ROCK inhibitor) (BioPioneer, 
San Diego, CA, catalog number SM-008) at 1.61 µg/ml in CGPM. After 1 hour, 
cells were gently rinsed with PBS and then incubated at 37°C for ~7 minutes 
with Stempro Accutase (Life Technologies, catalog number A1110501).57 The 
single cell suspensions were passed twice through a 40 µm filter to remove 
clumps and then resuspended in 1 ml of ice-cold CGPM with 2X Rock inhibitor. 
FACS purification was performed as described. PE-TexasRed-expressing cells 
(i.e., Stb) were collected and seeded at 1–1.5 × 106 cells/cm2. Stb-expressing 
PSCs were allowed to recover and expand for 1 week before a second round 
of FACS purification.58
OCT4SRE-mediated hiPSC cell killing with GCV in vitro
The in vitro functionality of OCT4SRE-driven TKO was examined by transducing 
AD2 hiPSC WT with lenti-pRRL-sin-cPPT-rArgO-rEF1α-OCT4SRE-eGFP-F2A- 
PAC-P2A-TKO at 20 MOI conferring eGFP, puromycin resistance, and TKO 
expression under OCT4SRE. The cells were allowed to recover and were puro-
mycin-selected for 72 hours before being twice FACS-purified for High35%-
eGFP-positive cells as described. The purified cells (AD2 hiPSC-TKO) were 
collected and converted to DCM conditions (AD2 DCM-d-TKO) as described.
For the in vitro GCV (Gemini Bio-Products, catalog number 
400-143P)-mediated cell death assay, AD2 hiPSC-TKO, AD2 DCM-d-TKO, and 
their WT counterparts were treated for 72 hours with either 2 μmol/l GCV or 
vehicle controls the day after passage for hiPSCs or immediately after day 7 
of DCM-d conversion. Cell death was determined by visual assessment under 
live microscopy.
Pluripotent state characterization and in vitro three germ layer 
differentiation
The OCT4-driven pluripotent state of the putative hiPSC-Stb candidate 
clones and parental AD2 fibroblasts (no OCT4 expression) were demon-
strated by immunophenotyping for common stemness markers.38 Alkaline 
phosphatase staining (AP) was performed according to the manufacturer’s 
recommendations (Stemgent, catalog number 00-0055). Light microscopy-
based imaging was performed with an AxioCam HR Color Camera using 
AxioVision Digital Image Processing Software version 4.7.2.0 (Axio Observer 
Inverted Microscope, Carl Zeiss, Oberkochen, Germany).42 ICC of cultured 
cells was performed by 20 minutes fixation in 4% paraformaldehyde, then 
washed once with PBS (supplemented with 100 mmol/l glycine) for 10 min-
utes, followed by washing twice with PBS for 5 minutes each. Samples to be 
examined for intracellular markers were permeabilized with 1% Triton-X100 
for 1 hour. Blocking was performed with 4% goat serum in casein-PBS for 1 
hour at room temperature. Primary antibodies were applied overnight at 4°C 
(Table 1). The pluripotent nature of the reprogrammed cells was examined in 
vitro by enabled tri-lineage differentiation into early mesoderm, endoderm 
and ectoderm (d-Stem-MicroStem, catalog number MS52013) under vali-
dated xeno-free and chemically defined conditions.
OCT4SRE inactivation
The construct response to a reduction in the OCT4 levels was examined 
by the conversion from CGPM to DCM containing 10% FBS (as previously 
described, this redirects the PSCs toward spontaneous FBS-mediated dif-
ferentiation with progressive and consistent reduction in the OCT4 levels 
within 1 week19,59) The functionality of the OCT4SRE in CGPM and DCM was 
assessed by flow cytometry, ICC, and qPCR for Stb expression linked to the 
OCT4SRE.
The in vitro construct functionality was additionally tested by transduc-
ing AD2 hiPSC WT with lenti-pRRL-rPAC-rp2A-rStb-rOCT4SRE-EF1α-eGFP at 20 
MOI conferring puromycin resistance. The cells were allowed to recover and 
were puromycin-selected for 72 hours before being twice FACS-purified for 
Stb/eGFP-double positive cells as described. The High35% Stb/eGFP-express-
ing cells (AD2 hiPSC C1P) were collected and converted to DCM conditions. 
This was performed for the demonstration of OCT4SRE-mediated puromycin 
resistance activation during pluripotent and puromycin resistance inactiva-
tion in response to DCM treatment.
Quantitative reverse transcription PCR
Total RNA was isolated from cultures with Roche High Pure RNA Isolation Kit 
(Roche Applied Sciences, Penzberg, Germany, catalog number 011828665001) 
and 10 ng-1 µg was reverse transcribed to cDNA utilizing Transcriptor First Strand 
cDNA Synthesis Kit (Roche Applied Sciences, catalog number 04379012001) 
following the manufacturer’s instructions. Primers and probes were designed 
from Roche’s Universal Probe Library. Primers for the genes were synthetized 
at Valuegene (San Diego, CA) and are listed in Table 2. Quantitative PCR relative 
expression experiments were performed on a LightCycler 480 Real-Time PCR 
System (Roche) and data was analyzed with LightCycler 480 Software (release 
1.5.0.) with 1–10 ng of sample in a 20 µl total reaction mix (10 μmol/l UPL probe, 
20 μmol/l each forward and reverse primer, and 20 μmol/l 2X LightCycler 480 
Probes master mix). Triplicate experimental samples were paired using the all-
to-mean pairing rule ΔCt value calculation with glyceraldehyde 3-phosphate 
dehydrogenase for advanced relative quantification.36,60
Statistical analysis
All collected data was analyzed with the SPSS (Armonk, NY) statistical 
package (Version 21.0). Results are expressed as mean and SD with a con-
fidence interval of 95%. The Levene test for equality of variances was used 
to analyze the normal distribution of the variables (P < 0.05). Quantitative 
data without a normal distribution was analyzed with nonparametric tests 
(Mann–Whitney U and Kolmogorov-Smirnov), whereas data with a normal 
distribution was analyzed with parametric tests as for independent sample 
t-test and two-way analysis of variance. Bonferroni and Dunnet T3 tests 
were performed for post-hoc analyses. P-values <0.05 were considered sta-
tistically significant. Correlation was established with a two-tailed Pearson 
correlation for variables with normal distribution. r2 values< 0.01 were 
considered a significant correlation. All graphs were generated utilizing 
GraphPad Prism 6 (La Jolla, CA).
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Table 2 PCR primer sequences
Gene Genbank ID Length Primer sequence Probe Amplicon
eGFP1a 723 F: 5′TCGTGACCACCCTGACCTAC3 ′; R: 5′GAAGTCGTGCTGCTTCATGT 3′ 41 71
eGFP2a 723 F: 5′GAAGCGCGATCACATGGT3 ′; R: 5′CCATGCCGAGAGTGATCC3 ′ 67 62
GAPDH ENST00000229239.5 1,875 F: 5′GCTCTCTGCTCCTCCTGTTC3 ′; R: 5′ACGACCAAATCCGTTGACTC3 ′ 60 115
OCT4 ENSG00000206454 1,086 F: 5′CTTCGGATTTCGTCTTCTCG3 ′; R: 5′CTTAGCCAGGTCCGAGGAT3 ′ 77 94
Stb 711 F: 5′TTGACCTCAGCGTCGTAGTG3 ′; R: 5′CTGAAGGGCGAGATCAAGA 3′ 41 65
TKO 1,131 F: 5′CTGCGGGTCTATATCGATGG3 ′; R: 5′AGTGCCACCAGGAGTTGTGT3 ′ 60 68
OCT4, Octamer-binding transcription factor 4; eGFP, enhanced green fluorescent protein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; TKO, Thymidine Kinase.
aeGFP1 and eGFP2 primer/probe sets were used for Figures 6 and 7, respectively.
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